Financial Ratios Shanghai RAAS Blood Products Co., Ltd.
Equities
002252
CNE100000C31
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.630 CNY | -0.53% |
|
-0.53% | -11.20% |
| Mar. 27 | RAAS Blood Products' 2025 Profit Slides 28%, Revenue Falls 10% | MT |
| Mar. 26 | Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.47 | 4.31 | 4.64 | 3.99 | 2.79 | |||||
Return on Total Capital | 3.58 | 4.54 | 4.95 | 4.25 | 2.92 | |||||
Return On Equity % | 5.05 | 6.85 | 6.08 | 7.12 | 4.9 | |||||
Return on Common Equity | 5.07 | 6.87 | 6.09 | 7.13 | 4.9 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 51.75 | 43.99 | 40.54 | 40.41 | 36.61 | |||||
SG&A Margin | 14.38 | 10.76 | 8.95 | 10.61 | 10.94 | |||||
EBITDA Margin % | 37.56 | 32.99 | 31.05 | 28.04 | 24.74 | |||||
EBITA Margin % | 34.35 | 30.44 | 29.18 | 26.3 | 22.37 | |||||
EBIT Margin % | 34.1 | 30.29 | 29.08 | 25.6 | 21.72 | |||||
Income From Continuing Operations Margin % | 30.06 | 28.52 | 22.32 | 26.83 | 21.46 | |||||
Net Income Margin % | 30.19 | 28.63 | 22.34 | 26.82 | 21.46 | |||||
Net Avail. For Common Margin % | 30.19 | 28.63 | 22.34 | 26.82 | 21.46 | |||||
Normalized Net Income Margin | 28.37 | 23.34 | 18.92 | 20.19 | 16.85 | |||||
Levered Free Cash Flow Margin | 17.46 | 17.97 | 20.01 | -14.96 | -14.35 | |||||
Unlevered Free Cash Flow Margin | 17.47 | 17.97 | 20.01 | -14.95 | -13.98 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.16 | 0.23 | 0.26 | 0.25 | 0.21 | |||||
Fixed Assets Turnover | 3.42 | 5.13 | 5.83 | 4.85 | 3.21 | |||||
Receivables Turnover (Average Receivables) | 6.97 | 8.39 | 9.43 | 6.33 | 3.64 | |||||
Inventory Turnover (Average Inventory) | 0.78 | 1.14 | 1.37 | 1.22 | 0.96 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 5.26 | 5.22 | 3.86 | 5.6 | 3.64 | |||||
Quick Ratio | 2.77 | 3.16 | 2.22 | 2.9 | 1.62 | |||||
Operating Cash Flow to Current Liabilities | 0.99 | 1.06 | 1.01 | -0.29 | -0.12 | |||||
Days Sales Outstanding (Average Receivables) | 52.38 | 43.5 | 38.72 | 57.86 | 100.3 | |||||
Days Outstanding Inventory (Average Inventory) | 470.73 | 319.64 | 267.33 | 298.95 | 378.41 | |||||
Average Days Payable Outstanding | 61.84 | 100.89 | 98.58 | 90.78 | 45.2 | |||||
Cash Conversion Cycle (Average Days) | 461.26 | 262.25 | 207.47 | 266.03 | 433.51 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 0.03 | 0.01 | 0.01 | 0.06 | 12.03 | |||||
Total Debt / Total Capital | 0.03 | 0.01 | 0.01 | 0.06 | 10.74 | |||||
LT Debt/Equity | 0.02 | 0.01 | 0 | 0.04 | 7.65 | |||||
Long-Term Debt / Total Capital | 0.02 | 0.01 | 0 | 0.04 | 6.83 | |||||
Total Liabilities / Total Assets | 4.89 | 5.4 | 7.14 | 5.03 | 14.1 | |||||
EBIT / Interest Expense | 3.1K | 7.56K | 19.34K | 9.31K | 36.18 | |||||
EBITDA / Interest Expense | 3.42K | 8.25K | 20.67K | 10.2K | 41.3 | |||||
(EBITDA - Capex) / Interest Expense | 2.99K | 7.39K | 16.91K | 8.39K | 32.58 | |||||
Total Debt / EBITDA | 0.01 | 0 | 0 | 0.01 | 2.14 | |||||
Net Debt / EBITDA | -1.83 | -1.94 | -1.7 | -1.29 | 0.99 | |||||
Total Debt / (EBITDA - Capex) | 0.01 | 0 | 0 | 0.01 | 2.72 | |||||
Net Debt / (EBITDA - Capex) | -2.1 | -2.17 | -2.07 | -1.57 | 1.25 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 55.26 | 53.16 | 21.27 | 2.67 | -10.13 | |||||
Gross Profit, 1 Yr. Growth % | 30.35 | 30.21 | 11.76 | 2.33 | -18.58 | |||||
EBITDA, 1 Yr. Growth % | 37.38 | 34.05 | 13.99 | -7.43 | -20.92 | |||||
EBITA, 1 Yr. Growth % | 40.54 | 35.26 | 16.06 | -7.63 | -23.76 | |||||
EBIT, 1 Yr. Growth % | 43.39 | 36.03 | 16.46 | -9.63 | -23.75 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -2.25 | 45.31 | -5.1 | 23.42 | -28.13 | |||||
Net Income, 1 Yr. Growth % | -2.21 | 45.24 | -5.35 | 23.25 | -28.1 | |||||
Normalized Net Income, 1 Yr. Growth % | 20.41 | 26.04 | -1.7 | 9.55 | -25.01 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -8.09 | 46.8 | -4.66 | 22.22 | -27.35 | |||||
Accounts Receivable, 1 Yr. Growth % | 11.95 | 40.94 | -15.44 | 133.87 | 22.81 | |||||
Inventory, 1 Yr. Growth % | 46.7 | 3.01 | 12.18 | 17.06 | 25 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 4.05 | 0.23 | 13.35 | 32.33 | 38.5 | |||||
Total Assets, 1 Yr. Growth % | 6.84 | 11.83 | 4.83 | 5.33 | 12.34 | |||||
Tangible Book Value, 1 Yr. Growth % | 5.84 | 14.88 | 1.61 | 8.39 | -10.78 | |||||
Common Equity, 1 Yr. Growth % | 3.1 | 11.26 | 2.83 | 7.74 | 1.66 | |||||
Cash From Operations, 1 Yr. Growth % | 10.71 | 33.35 | 32.01 | -121.16 | -31.81 | |||||
Capital Expenditures, 1 Yr. Growth % | -18.73 | 10.32 | 99.71 | -9.68 | -5.48 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 32.56 | 57.64 | 35.03 | -176.73 | -13.75 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 32.56 | 57.6 | 35.02 | -176.72 | -15.99 | |||||
Dividend Per Share, 1 Yr. Growth % | 12 | 7.14 | 0 | 133.33 | -31 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 28.79 | 54.21 | 36.29 | 11.58 | -3.94 | |||||
Gross Profit, 2 Yr. CAGR % | 16 | 30.28 | 20.63 | 6.94 | -8.72 | |||||
EBITDA, 2 Yr. CAGR % | 24.18 | 35.94 | 23.69 | 2.81 | -14.33 | |||||
EBITA, 2 Yr. CAGR % | 26.37 | 38.13 | 25.38 | 3.63 | -15.97 | |||||
EBIT, 2 Yr. CAGR % | 27.74 | 39.67 | 25.87 | 2.59 | -16.99 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 45.85 | 19.18 | 17.43 | 8.23 | -5.82 | |||||
Net Income, 2 Yr. CAGR % | 45.93 | 19.18 | 17.24 | 8.01 | -5.86 | |||||
Normalized Net Income, 2 Yr. CAGR % | 48.42 | 23.19 | 11.31 | 3.77 | -9.36 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 25.83 | 16.15 | 18.3 | 8.77 | -5.77 | |||||
Accounts Receivable, 2 Yr. CAGR % | -13.2 | 25.61 | 9.17 | 40.63 | 69.48 | |||||
Inventory, 2 Yr. CAGR % | 28.79 | 22.93 | 7.5 | 14.59 | 20.96 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 6.1 | 2.12 | 6.59 | 22.47 | 35.38 | |||||
Total Assets, 2 Yr. CAGR % | 51.59 | 9.3 | 8.27 | 5.08 | 8.78 | |||||
Tangible Book Value, 2 Yr. CAGR % | 87.87 | 10.27 | 8.04 | 4.95 | -1.66 | |||||
Common Equity, 2 Yr. CAGR % | 50.22 | 7.1 | 6.96 | 5.25 | 4.65 | |||||
Cash From Operations, 2 Yr. CAGR % | 21.77 | 21.5 | 32.68 | -47.15 | -62.01 | |||||
Capital Expenditures, 2 Yr. CAGR % | 14.94 | -5.31 | 48.43 | 34.3 | -7.61 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 20.18 | 44.56 | 45.9 | 1.79 | -18.64 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 20.08 | 44.54 | 45.87 | 1.78 | -19.71 | |||||
Dividend Per Share, 2 Yr. CAGR % | 67.33 | 9.54 | 3.51 | 52.75 | 26.89 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 33.45 | 36.45 | 42.34 | 24.01 | 3.82 | |||||
Gross Profit, 3 Yr. CAGR % | 23.19 | 20.55 | 23.79 | 14.19 | -2.35 | |||||
EBITDA, 3 Yr. CAGR % | 40.22 | 27.53 | 28.24 | 12.36 | -5.72 | |||||
EBITA, 3 Yr. CAGR % | 47.4 | 29.43 | 30.41 | 13.3 | -6.36 | |||||
EBIT, 3 Yr. CAGR % | 49.86 | 30.44 | 31.46 | 12.71 | -7.07 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -5.41 | 45.67 | 10.47 | 19.4 | -5.58 | |||||
Net Income, 3 Yr. CAGR % | -5.18 | 45.7 | 10.37 | 19.21 | -5.69 | |||||
Normalized Net Income, 3 Yr. CAGR % | 68.73 | 40.55 | 14.26 | 10.72 | -6.88 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -15.06 | 32.46 | 8.75 | 20.2 | -4.92 | |||||
Accounts Receivable, 3 Yr. CAGR % | -12.09 | 2.02 | 10.09 | 40.73 | 34.42 | |||||
Inventory, 3 Yr. CAGR % | 23.57 | 19.55 | 19.24 | 10.6 | 17.96 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 4.32 | 4.1 | 5.74 | 14.56 | 27.6 | |||||
Total Assets, 3 Yr. CAGR % | 33.73 | 36.97 | 7.79 | 7.28 | 7.45 | |||||
Tangible Book Value, 3 Yr. CAGR % | 59.21 | 59.46 | 7.3 | 8.16 | -0.58 | |||||
Common Equity, 3 Yr. CAGR % | 33.54 | 35.91 | 5.66 | 7.22 | 4.04 | |||||
Cash From Operations, 3 Yr. CAGR % | 70.19 | 25.51 | 24.91 | -28.05 | -42.46 | |||||
Capital Expenditures, 3 Yr. CAGR % | 9.24 | 13.38 | 21.43 | 25.78 | 19.46 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 88.26 | 31.56 | 41.31 | 17.77 | -3.68 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 119.37 | 31.47 | 41.29 | 17.75 | -4.53 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | 44.22 | 6.27 | 35.72 | 17.2 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 13.01 | 27.78 | 34.58 | 25.9 | 21.62 | |||||
Gross Profit, 5 Yr. CAGR % | 8.41 | 18.77 | 22.16 | 14.91 | 9.59 | |||||
EBITDA, 5 Yr. CAGR % | 5.81 | 19.02 | 33.45 | 17.03 | 9.17 | |||||
EBITA, 5 Yr. CAGR % | 5.79 | 20.46 | 38.27 | 18.45 | 9.42 | |||||
EBIT, 5 Yr. CAGR % | 5.82 | 21.09 | 39.76 | 18.49 | 9.38 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -4.82 | 17.62 | 3.14 | 29.35 | 3.64 | |||||
Net Income, 5 Yr. CAGR % | -4.31 | 17.6 | 3.22 | 29.26 | 3.56 | |||||
Normalized Net Income, 5 Yr. CAGR % | 2.36 | 16.12 | 42.87 | 24.49 | 4.26 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -10.45 | 10.41 | -3.02 | 22.42 | 3.01 | |||||
Accounts Receivable, 5 Yr. CAGR % | -8.26 | -3.89 | -4.13 | 16 | 30.82 | |||||
Inventory, 5 Yr. CAGR % | 31.63 | 23.14 | 16.87 | 17.54 | 19.92 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 1.76 | 2.79 | 5.22 | 11.1 | 16.72 | |||||
Total Assets, 5 Yr. CAGR % | 15.54 | 16.07 | 22.9 | 23.19 | 8.19 | |||||
Tangible Book Value, 5 Yr. CAGR % | 29.01 | 29.59 | 36.34 | 34.89 | 3.62 | |||||
Common Equity, 5 Yr. CAGR % | 17.21 | 18.25 | 22.19 | 22.7 | 5.26 | |||||
Cash From Operations, 5 Yr. CAGR % | 15.18 | 45.05 | 54.06 | -11.19 | -22.41 | |||||
Capital Expenditures, 5 Yr. CAGR % | 6.77 | 7.42 | 23.5 | 21.33 | 8.86 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 1.53 | 11.36 | 70.01 | 18.73 | 13.31 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 0.92 | 12.84 | 86.34 | 18.68 | 12.7 | |||||
Dividend Per Share, 5 Yr. CAGR % | -1.37 | 12.03 | - | 47.58 | 14.08 |
Select your edition
All financial news and data tailored to specific country editions
















